TEVA- PHARMACEUTICAL INDUSTRIES LTD (TEVA)

2026-07-31. The following slide deck was published by Teva Pharmaceutical Industries Limited in conjunction with their 2026 Q2 earnings call.

TEVA misses Q2 earnings estimates as Emalex acquisition costs weigh on profits, while innovative drugs drive a revenue beat and an increased 2026 sales outlook.

In the past week, Teva Pharmaceutical Industries reported Q2 2026 results showing largely flat sales of US$4,142 million year-on-year but shifting from net income of US$282 million to a net loss of US$576 million, driven in part by impairment charges and acquisition-related costs.

Teva Pharmaceutical Industries (NYSE:TEVA) stock is reacting to a mixed update after the company raised its 2026 revenue guidance while reporting a quarterly net loss and new asset impairment charges. See our latest analysis for Teva Pharmaceutical Industries. The earnings update and higher ...

Revenue: Approximately $4.1 billion, down 1% in U.S. Dollars or 3% in local currency compared to Q2 2025.Net Loss: $576 million.Non-GAAP Gross Margin: 55.4%, an